In this episode of LongeCity interview, Dr. Brad Stanfield discusses his upcoming research into the use of rapamycin for slowing down aspects of human ageing, focusing on muscle performance in older adults.

Key Points:

Dr. Brad Stanfield’s research aims to test rapamycin’s potential to improve muscle performance in ageing adults by targeting mTOR, a key regulator of cellular ageing. This trial could pave the way for new interventions in healthy ageing and longevity.

• Background on Rapamycin: Rapamycin is traditionally used in medicine to prevent organ rejection but has shown promise in extending lifespan in mice through its effect on mTOR, an enzyme that regulates cell metabolism and ageing processes.
• Proposed Study: Dr. Stanfield aims to test whether intermittent rapamycin use, combined with exercise, can improve muscle performance in older adults, targeting mTOR regulation to balance muscle growth and cell clearance (autophagy).
• Focus on Functional Outcomes: The trial will use the 30-second chair stand test as a primary measure, assessing how rapamycin impacts physical abilities in participants aged 65-85.
• Phased Approach: Initially, a small phase II trial with around 40 participants will assess safety and feasibility, with a larger, multi-center trial planned if successful.
• Potential Side Effects: While rapamycin is known for its immune-modulating effects, the trial will use lower, intermittent doses to minimize risks, focusing on its potential to improve muscle function rather than suppress immunity.
• Crowdfunding and Support: The study is being funded through lifespan.io and Dr. Stanfield’s YouTube channel, encouraging public donations to advance human research in longevity.